# A post-vacation weight increase during GLP-1 maintenance

A short-term scale change can include water and other mass, not just fat. The pattern over time is more informative than one post-travel reading.

Canonical: https://velri.co/blog/glp1-maintenance-temporary-regain-vacation-optimizer-provider-reads
Publisher: Velri (https://velri.co/about)
Published: 2026-06-26
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

One higher scale reading after a vacation cannot tell you how much body fat changed. Body weight includes water and stored carbohydrate as well as fat and other tissues. Glycogen, the body's stored carbohydrate, is held with water, so changes in its storage can affect weight. [1]

That makes a short-term increase different from a sustained upward trend during maintenance.

## Why can the scale move quickly?

Research on glycogen storage has shown how dietary changes can produce weight fluctuations through associated water. The study was small and examined a restrictive-diet setting; it does not calculate how much of a particular vacation increase is water. [1]

Bowel patterns may also change during travel. NIDDK lists travel, changes in eating, inadequate fluid and some medicines among contributors to constipation. Constipation is also a recognized adverse reaction with semaglutide and tirzepatide. [2][3][4]

## What makes a trend more interpretable?

Comparisons are clearer when the scale and measurement conditions are consistent. Include the dates and note the travel period, bowel changes and any interruption in the prescribed treatment. This creates a more useful record than comparing the lowest pre-trip reading with the highest post-trip reading.

If a rise continues, it belongs in the maintenance review. The discussion can examine whether the current treatment remains effective and tolerable, rather than assuming that a single reading requires a medication change. [5]

## Why medication changes are a separate question

A randomized tirzepatide withdrawal trial found substantially more regain after switching to placebo than after continuing treatment. That supports taking treatment continuity seriously, but the study measured outcomes over months. It does not explain a brief change after a trip. [6]

A persistent upward trend is a reason to review maintenance, with the travel period and treatment history in view.

## Sources
[1] Glycogen storage: illusions of easy weight loss, excessive weight regain, and distortions in estimates of body composition. (1992). https://pubmed.ncbi.nlm.nih.gov/1615908/
[2] Symptoms & Causes of Constipation - NIDDK (2018). https://www.niddk.nih.gov/health-information/digestive-diseases/constipation/symptoms-causes
[3] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[4] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[5] Prescription Medications to Treat Overweight & Obesity - NIDDK (2025). https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[6] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. (2024). https://pubmed.ncbi.nlm.nih.gov/38078870/

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support